Mallinckrodt plc Files Definitive Proxy Statement

TL;DR

Mallinckrodt's proxy statement is in, shareholders vote soon.

AI Summary

Mallinckrodt plc filed a definitive proxy statement (DEF 14A) on August 20, 2025, for its fiscal year ending December 26, 2025. The filing, which requires no fee, pertains to the company's annual meeting and related shareholder matters. Mallinckrodt is incorporated in L2 and headquartered in Dublin, Ireland.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda for the annual meeting, including voting on important corporate matters and the election of directors.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not contain new financial information or material events.

Key Players & Entities

• Mallinckrodt plc (company) — Registrant
• 0001104659-25-080554 (filing_id) — Accession Number
• 20250820 (date) — Filing Date
• 20251008 (date) — Period of Report
• 1226 (date) — Fiscal Year End
• Dublin (location) — Company Headquarters

FAQ

Key Financial Figures

• $0.01 — (a) THAT , the Preferred Shares of US$0.01 each in the authorized share capital of
• $0.001 — sub-divided into Preferred Shares of US$0.001 each, having the rights and being subje
• $10,000,000 — Resolution 2(a) above, will stand at US$10,000,000 and €25,000 divided into 500,000,0
• $3,005,000,000 — hare capital of Mallinckrodt shall be US$3,005,000,000 and €25,000 divided into 500,000,0

Filing Documents

• tm2521878-3_def14a.htm (DEF 14A) — 303KB
• lg_mallinckrodt-4c.jpg (GRAPHIC) — 17KB
• px_25mallinckpx1pg01-bw.jpg (GRAPHIC) — 259KB
• px_25mallinckpx1pg02-bw.jpg (GRAPHIC) — 306KB
• sg_marktyndall-bw.jpg (GRAPHIC) — 8KB
• sg_paulefron-bw.jpg (GRAPHIC) — 5KB
• 0001104659-25-080554.txt ( ) — 1096KB

From the Filing

DEF 14A 1 tm2521878-3_def14a.htm DEF 14A tm2521878-3_def14a - none - 3.5468733s TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 Mallinckrodt public limited company (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. TABLE OF CONTENTS PROXY STATEMENT—YOUR VOTE IS VERY IMPORTANT MALLINCKRODT PUBLIC LIMITED COMPANY College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, D15 TX2V, Ireland August 20, 2025 Dear Shareholder, This serves as notice to you of an extraordinary general meeting (the "EGM") of the shareholders of Mallinckrodt plc ("Mallinckrodt"), which will be held on October 8, 2025, at 9:30 a.m. local time, at the offices of Arthur Cox LLP, Ten Earlsfort Terrace, Dublin 2, D02 T380, Ireland. The purpose of the EGM is to ask shareholders to approve a special resolution to change the name of Mallinckrodt from Mallinckrodt plc to Keenova Therapeutics plc, as well as ordinary resolutions to effect a sub-division, variation and increase in Mallinckrodt's authorized share capital to create greater flexibility for the issuance of preferred shares in the Company's share capital. The enclosed Notice of Extraordinary General Meeting of Shareholders and the accompanying proxy statement set forth more detail on the proposals that will be presented at the EGM. We urge all Mallinckrodt shareholders to read the accompanying proxy statement carefully and in its entirety. Your proxy is being solicited by the Board of Directors of Mallinckrodt. The Board of Directors of Mallinckrodt unanimously recommends that you vote "FOR" the resolutions at the EGM described in the accompanying proxy statement. Whether or not you expect to attend the EGM, we encourage you to cast your vote promptly so that your shares will be represented and voted at the meeting. This can be done in advance of the EGM by availing yourself of one of the options detailed in the accompanying proxy statement. On behalf of the Board of Directors of Mallinckrodt, I extend our appreciation for your continued support. Yours sincerely, PAUL EFRON Chairman of the Board of Directors of Mallinckrodt plc The accompanying proxy statement is dated August 20, 2025, and is first being mailed to shareholders of Mallinckrodt on or about September 10, 2025. TABLE OF CONTENTS MALLINCKRODT PUBLIC LIMITED COMPANY College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, D15 TX2V, Ireland NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF MALLINCKRODT PUBLIC LIMITED COMPANY NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the "EGM") of the shareholders of Mallinckrodt plc ("Mallinckrodt" or the "Company," "we," "our" or "us"), a public limited company incorporated under the laws of Ireland, will be held on October 8, 2025 at 9:30 a.m. local time, at the offices of Arthur Cox LLP, Ten Earlsfort Terrace, Dublin 2, D02 T380, Ireland, for the purposes of considering and, if thought fit, passing the following resolutions: 1. Special Resolution: Approval of the Change of Name of the Company THAT , the change of the name of the Company from Mallinckrodt plc to Keenova Therapeutics plc is hereby approved, subject to the approval of the Registrar of Companies, and the memorandum and articles of association of the Company be amended to reflect this change of name, and the board of directors of the Company is hereby authorized in its absolute discretion to determine the time of the filing with the Registrar of Companies of the relevant applications, forms, filings and documents for such change of name and whether or not to proceed with filing such applications, forms, filings and documents, with the power to delegate and sub-delegate the determination of all of the foregoing, provided that the authority conferred by this resolution shall expire on October 7, 2026 if the relevant applications, forms, filings and documents for such change of name have not been filed with the Registrar of Companies on or before such date, and provided further that this resolution shall have effect from the business day immediately prior to such filing with the Registrar of Companies (such resolution is sometimes referred to as "Resolution 1" in th

View Full Filing

View this DEF 14A filing on SEC EDGAR